Sun Pharma March-quarter net profit rises 57 percent

Thu May 29, 2014 6:56pm IST

A man carrying a gas cylinder walks out of the research and development centre of Sun Pharmaceutical Industries Ltd in Mumbai May 29, 2014. REUTERS/Danish Siddiqui

A man carrying a gas cylinder walks out of the research and development centre of Sun Pharmaceutical Industries Ltd in Mumbai May 29, 2014.

Credit: Reuters/Danish Siddiqui

Related Topics

Stocks

   

REUTERS - Sun Pharmaceutical Industries Ltd (SUN.NS), India's third-largest drugmaker by revenue, on Thursday reported a 57 percent jump in fourth-quarter net profit, slightly above expectations, helped by higher sales in the United States, its largest market.

The company, which is in the process of acquiring loss-making rival Ranbaxy Laboratories Ltd (RANB.NS), posted a net profit of 15.87 billion rupees ($269.55 million) in January-March, compared with 10.12 billion rupees a year earlier. Analysts on average expected 15.74 billion rupees, according to Thomson Reuters data.

Sales in January-March rose 32 percent to 40.44 billion rupees. The company also said it expects a 13 to 15 percent growth in sales in full-year 2015.

Sun Pharma, a bellwether in India's $15-billion pharmaceutical industry, agreed in April to buy Ranbaxy from Japan's Daiichi Sankyo Ltd (4568.T) for $3.2 billion, creating the world's fifth-largest maker of generic drugs.

The drugmaker, however, faces an uphill task in turning around Ranbaxy's business and fixing manufacturing quality issues that have resulted in several Ranbaxy plants being barred from exporting to the United States.

Sun Pharma is also working towards resolving quality control issues that got its Karkhadi, India, plant banned by the U.S. Food and Drug Administration in March.

The company's shares, which are up 4 percent so far this year, ended 0.43 percent higher, while the Nifty was down 1.3 percent.

($1 = 58.8750 rupees)

(Reporting by Zeba Siddiqui in Mumbai; Editing by Sunil Nair)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

BACK IN JAIL

REUTERS SHOWCASE

Modi Hurdle

Modi Hurdle

Appointment of Arvind Subramanian as chief economic adviser hits Modi hurdle.  Full Article 

USL Board

USL Board

Diageo bars United Breweries from appointing independent director at United Spirits.  Full Article 

Amazon in India

Amazon in India

Amazon to sell packaged food and beverages in India - Economic Times.  Full Article 

iOS 8 Issue

iOS 8 Issue

iOS 8 causing Bluetooth connectivity issues - Apple news blog  Full Article 

NYT Job Cut

NYT Job Cut

New York Times to cut jobs as new products disappoint  Full Article 

Factory Activity

Factory Activity

Factories expand at slowest pace this year in September  Full Article 

Monetary Policy

Monetary Policy

RBI not biased towards either raising or cutting rates - Rajan  Full Article 

Weak Demand

Weak Demand

Weak demand hits factory activity across Asia, Europe  Full Article 

Pimco Fund

Pimco Fund

Pimco Total Return Fund posts record $23.5 bln net outflow in Sept  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage